The invention discloses a substituted
diaryl ether compound. The
structural formula of the compound is shown in the specification. In the
structural formula, Z is -CH- or -N-; W is -CH-or -N-; Y is -O-, -CH2-, -NH- or -NRy-; R1 is one of
hydrogen,
halogen, NO2, CN, CF3, ORa, CORa, COORa, SO2Ra, SO2NRaRb, NRaRb, NRaCORb, a non-substituted / substituted C1-C4
alkyl group, a non-substituted / substituted
aryl group and a non-substituted / substituted heterocyclic group; R2 is
hydrogen, a non-substituted / substituted C1-C4
alkyl group, or
halogen; and R is one of a non-substituted / substituted C1-C12
alkyl group, a non-substituted / substituted C3-C12 cycloalkyl group, a non-substituted / substituted C2-C12 alkenyl group, a non-substituted / substituted
aryl group, substituted alkylamine, and a non-substituted / substituted heterocyclic group. The substituted
diaryl ether compound can obviously inhibit the malignant proliferation
phenotype of
cancer cells, promotes the expression of
cell apoptosis factor proteins, and provides a new potential
anticancer drug.